Biotechnology - Biotechnology, Boehringer Ingelheim

Filter

Popular Filters

EPIC Biotech conference: essential to prove comercial viability of propositions

EPIC Biotech conference: essential to prove comercial viability of propositions

03-10-2014

The key message from European Partnering and Investment Conference in biotech, held yesterday in London,…

Antibiotics and Infectious diseasesBiotechnologyBoehringer IngelheimCardio-vascularCNS DiseasesFinancialJohnson & JohnsonMerck SeronoOncologyResearch

Boehringer Ingelheim and CureVac link on lung cancer immunotherapy

Boehringer Ingelheim and CureVac link on lung cancer immunotherapy

21-09-2014

Family-owned German drug major Boehringer Ingelheim and German clinical-stage biotech company CureVac…

BiotechnologyBoehringer IngelheimCureVacCV9202GlobalLicensingOncology

NSCLC treatment market set to grow to more than $7.9 billion by 2020

NSCLC treatment market set to grow to more than $7.9 billion by 2020

09-09-2014

The global non-small cell lung cancer treatment market value will increase from $5.1 billion in 2013…

BiotechnologyBoehringer IngelheimBristol-Myers SquibbEli LillyGilotrifGlobalMarkets & MarketingnecitumumabnivolumabOncologyYervoy

Boehringer’s nintedanib slows IPF disease progression in Ph III trial

19-05-2014

Results from the Phase III INPULSIS trials, published on-line yesterday in the New England Journal of…

BiotechnologyBoehringer IngelheimnintedanibResearchRespiratory and Pulmonary

Boehringer Ingelheim launches diabetes collaboration with Connexios Life Sciences

Boehringer Ingelheim launches diabetes collaboration with Connexios Life Sciences

06-05-2014

German family-owned drug major Boehringer Ingelheim has announced a global research collaboration with…

BiotechnologyBoehringer IngelheimDiabetesGermanyHealth Medical PharmaHealth Medical PharmaIndiaIngelheim am RheinLicensingMajorResearch

Vitae Pharma earns $14 million milestone from Boehringer Ingelheim in Alzheimer's collaboration

Vitae Pharma earns $14 million milestone from Boehringer Ingelheim in Alzheimer's collaboration

20-02-2014

US clinical-stage biotech firm Vitae Pharmaceuticals says it has earned a $14 million milestone payment…

BiotechnologyBoehringer IngelheimFinancialNeurologicalResearchVitae Pharmaceuticals

arGEN-X reaches two milestone payments in Shire deal and signs research agreement with Boehringer

13-01-2014

Belgium-based biotech firm arGEN-X has reached two important success milestones in its SIMPLE Antibody…

arGEN-XBelgiumBiotechnologyBoehringer IngelheimFinancialGeneticsLicensingRare diseasesResearchShire

AASLD meeting highlights: Gilead’s sofosbuvir, Janssen’s simeprevir and Boehringer’s faldaprevir

03-11-2013

Among research results released at this week at the 64th Annual Meeting of the American Association for…

Anti-viralsBiotechnologyBoehringer IngelheimfaldaprevirGilead SciencesJanssenJohnson & JohnsonPharmaceuticalResearchsimeprevirsofosbuvir

Polyphor-Boehringer Ingelheim alliance moves forward

01-08-2013

Privately-held Swiss biotechnology company Polyphor has entered into the next stage of its drug discovery…

BiotechnologyBoehringer IngelheimEuropePolyphorResearch

US FDA approves Boehringer Ingelheim's first cancer drug

15-07-2013

In what the family-owned German drug major Boehringer Ingelheim hopes is just the first drug to come…

afatinibBiotechnologyBoehringer IngelheimGilotrifNorth AmericaOncologyPharmaceuticalQiagenRegulation

Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis

19-06-2013

Sweden-based Athera Biotechnologies, which is 65% owned by Karolinska Development, has entered into an…

Athera BiotechnologiesBiotechnologyBoehringer IngelheimCardio-vascularKarolinska DevelopmentLicensing

Gilead gains FDA priority review for hep C candidate sofosbuvir; new data on Boehringer's faldaprevir

10-06-2013

US biotech firm Gilead Sciences (Nasdaq: GILD) revealed on Friday (June 7) that the US Food and Drug…

Anti-viralsAsia-PacificBiotechnologyBoehringer IngelheimfaldaprevirGilead SciencesNorth AmericaPharmaceuticalRegulationResearchsofosbuvir

Boehringer Ingelheim to build biopharma facility in China

07-06-2013

German family-owned drug major Boehringer Ingelheim has signed a strategic alliance agreement and contract…

Asia-PacificBiotechnologyBoehringer IngelheimFinancialPharmaceuticalProductionShanghai Zhangjiang Biotech

US pulmonologists view refractory asthma patient treatment with biosimilar Xolair by end-2018

10-04-2013

US pulmonologists surveyed by health care advisory firm Decision Resources estimate that only 19% percent…

BiotechnologyBoehringer IngelheimGenentechGenericsMarkets & MarketingNorth AmericaNovartisPfizerRespiratory and PulmonarySpirivaXolair

Regulatory briefs on Bayer's Stivarga, Boehringer/Lilly's empagliflozin and Pfizer's Xeljanz

26-03-2013

Drug regulator Health Canada has approved German drug major Bayer's Stivarga (regorafenib tablets), indicated…

Anti-Arthritics/RheumaticsAsia-PacificBayerBiotechnologyBoehringer IngelheimDiabetesEli LillyempagliflozinNorth AmericaOncologyPfizerPharmaceuticalRegulationStivargaXeljanz

SOBI gains EMA approval for change of Kineret producer; Novartis drops NIC002 project

23-01-2013

Swedish Orphan Biovitrum (STO: SOBI) has received approval from the European Medicines Agency for the…

BiotechnologyBoehringer IngelheimCytos BiotechnologyKineretLicensingNIC002NovartisPharmaceuticalProductionRegulationSwedish Orphan Biovitrum

Highlights from ASH meeting on Eliquis, Pradaxa, ALN-TMP and ibrutinib

11-12-2012

During the 54th Annual Meeting of the American Society of Hematology (ASH) now taking place in Atlanta,…

ALN-TMPAlnylam PharmaceuticalsBiotechnologyBoehringer IngelheimBristol-Myers SquibbCardio-vascularEliquisibrutinibOncologyPfizerPharmaceuticalPharmacyclicsPradaxaResearch

Flood of new cancer drug data presented at ASCO; nearly 1,000 being tested

04-06-2012

The annual prestigious American Society of Clinical Oncology (ASCO) meeting taking place in Chicago,…

afatinibBiotechnologyBoehringer IngelheimGenentechJanssenJohnson & JohnsonOncologyPharmaceuticalResearchRochetrastuzumab emtansineZytiga

Promethera raises 23.6 million euros, with backers including Shire and Boehringer

28-03-2012

Belgian cell therapy company Promethera Biosciences yesterday completed a fundraising round that generated…

BiotechnologyBoehringer IngelheimFinancialHepaStemNephrology and HepatologyPromethera BiosciencesRegulationShire

Ablynx extends Nanobody deal with Boehringer

21-03-2012

Belgian drug developer Ablynx (Euronext Brussels: ABLX) yesterday announced a two-year extension of the…

AblynxBiotechnologyBoehringer IngelheimImmunologicalsLicensingOncologyPharmaceuticalRespiratory and Pulmonary

Boehringer Ingelheim links with Xencor on MAb supply

23-02-2012

Independent German drug major Boehringer Ingelheim has entered into a collaboration agreement with USA-based,…

BiotechnologyBoehringer IngelheimLicensingPharmaceuticalXencor

Back to top